SCN9A-ANTISENSE-OLIGONUKLEOTIDE

European patent · EP3512870 · In force

Register entry

Publication number
EP3512870
Application number
EP17850354
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 24, 2017
Published
Jul 24, 2019
Granted
Aug 3, 2022
Protection ends at the latest
May 23, 2037
Next annual fee due
May 31, 2027
IPC classes
C12N 15/113 (2010.01)
A61K 31/7088 (2006.01)
A61P 25/02 (2006.01)
Priority
US 201662395814 P 16.09.2016
PCT application
PCT/IB2017/000751 24.05.2017
PCT publication
WO2018/051175 22.03.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2026

    Change

    Published in Swissreg on 01.06.2026

  2. Nov 26, 2025

    Change

    Published in Swissreg on 26.11.2025

  3. Jun 2, 2024

    Change

    Published in Swissreg on 02.06.2024

  4. Jun 14, 2023

    Change

    Published in Swissreg on 14.06.2023

  5. Jun 1, 2023

    Change

    Published in Swissreg on 01.06.2023

  6. Sep 8, 2022

    Agent entered

    Representative
    HGF GmbH, OBC Suisse AG, Aeschengraben 29, 4051 Basel

    Published in Swissreg on 08.09.2022

  7. Aug 3, 2022

    Granted

    Published in Swissreg on 03.08.2022

Parties

Holder

Olipass Corporation

20th Floor Ace Dongbaek Tower 16 Beon-gil 16-7 Dongbaek Jungang-ro Giheung-gu, Yongin-si, Gyeonggi-do 17015, KR

Agent

HGF GmbH

HGF GmbH OBC Suisse AG

Aeschengraben 29, 4051 Basel

Inventor

CHO, Bongjun

Yongin-si Gyeonggi-do 17077, KR

CHUNG, Shin

Yongin-si Gyeonggi-do 16990, KR

YOON, Heungsik

Seongnam-si Gyeonggi-do 13623, KR

JUNG, Daram

Hwaseong-si Gyeonggi-do, KR

JANG, Kangwon

Yongin-si Gyeonggi-do 16998, KR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.